The characteristic biochemical testing pattern for MADD includes elevations in multiple short-, medium-, and long-chain acylcarnitine species and elevations in specific urine organic acids and urine acylglycines that are characteristic of the multiple dehydrogenases that interact with ETF and ETF-DH. Here, TEAD2 is linked to multiple acyl-CoA dehydrogenase deficiency.